X0306 4 2018-05-15 1 0001652923 AveXis, Inc. AVXS 0001206199 WELCH DANIEL G C/O AVEXIS, INC. 2275 HALF DAY ROAD, SUITE 200 BANNOCKBURN IL 60015 1 0 0 0 Common Stock 2018-05-15 4 D 0 1106 0.00 A 0 D Stock Option (Right to Buy) 20.00 2018-05-15 4 D 0 35552 0.00 D 2026-02-10 Common Stock 35552 0 D Stock Option (Right to Buy) 69.25 2018-05-15 4 D 0 2454 0.00 D 2027-05-30 Common Stock 2454 0 D Stock Option (Right to Buy) 133.80 2018-05-15 4 D 0 2905 0.00 D 2028-03-13 Common Stock 2905 0 D On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. /s/ Madison Jones, Attorney-in-Fact 2018-05-15